(Q42872791)

English

Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model

scientific article published on September 28, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Hye-Sung Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Hye-Mi Park

2

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Jung-Sun Park

3

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Hyun-Jung Sohn

4

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Sung-Guh Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Hyung-Jin Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Seong-Taek Oh

7

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Tai-Gyu Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

language of work or name

0 references

publication date

28 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0264410X10013563?httpAccept=text/xml

1 reference

10.1016/J.VACCINE.2010.09.046

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.046

23 July 2024

https://api.elsevier.com/content/article/PII:S0264410X10013563?httpAccept=text/plain

1 reference

10.1016/J.VACCINE.2010.09.046

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.046

23 July 2024

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

7787-7796

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Immunotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Cancer immunotherapy: a treatment for the masses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Carcinoembryonic antigen gene family: molecular biology and clinical perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Exploiting dendritic cells to improve vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Regulatory T cells, tumour immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Lack of interferon gamma receptor beta chain and the prevention of interferon gamma signaling in TH1 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

The role of stroma in immune recognition and destruction of well-established solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.046

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.09.046

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42872791&oldid=2211146688"